Abstract: A monolithic, fully-immersed spectrometer using crossed cylindrical lenses enables independent focusing of the incoming beam along the two principal axes, e.g. x-axis and y-axis, perpendicular to the optical axis. A first lens “flattens” the beam before entering the body of a second curved, reflective lens, so the second lens only needs to focus in one axis. This restricts the curvature to 1-dimension and therefore reduces the thickness of the device by an order of magnitude compared to a design based on spherical lenses. A cylindrical-based design greatly increases manufacturability and scalability.

Abstract: The present invention relates to compositions comprising: malt extract including a plurality of enzymatically active enzymes including at least fructanase and amylase; one or more medium-chain triglycerides (MCTs) and/or at least one biologically acceptable metal component and use of those compositions as veterinary and human medicaments.

Abstract: The invention concerns the improvement of metabolic and digestive health of humans by providing diagnostic methods for enterometabolic disorders such as IBS and IBD and/or the treatment of IBS and IBD by compositions comprising enzyme rich malt extract (ERME).

Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.

Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof. The present invention also provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.

Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.

Abstract: The present invention is directed to combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.

Abstract: A downhole flow control device is described having a flow control valve and a sensor communication with the flow control valve. The sensor measures a downstream process parameter and the flow control valve is configured to control the fluid flow through the valve to achieve a target downstream process parameter value in response to the measured downstream process parameter. A control system for controlling the downhole flow control device and a method for controlling the downhole flow device are also provided.

Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof.

Abstract: The present invention relates to an anti-ILDR2 antibody, a fragment or derivative thereof, a modified antibody format, or an antibody mimetic for use in combination with a PD-1 antagonist in the treatment of cancer. Other aspects of the present invention relate to a combination comprising an anti-ILDR2 antibody and a PD-1 antagonist and the use of such combination as a medicament, as well as methods of treatment or prophylaxis of a cancer in a subject, comprising administering to said subject a therapeutically effective amount of the antibodies as described herein. Further, the present invention relates to a kit comprising anti-ILDR2 antibodies and PD-1 antagonists and optionally one or more further pharmaceutical agents.

Abstract: A power source system including a plurality of cells. The power source system uses electrical charge or current generated by a reaction in at least one of the cells to provide at least one operating material to at least one other of the cells. Optionally, the power source system uses the electrical charge generated by the reaction in the at least one of the cells to provide the at least one operating material to the at least one other of the cells only when the state of charge of the at least one of the cells is equal to or below a threshold or when the use of the cell is equal to or above a threshold. Optionally, in an initial or non-operational state, one or more or each of the cells is dry or without the at least one operating material and the power source system is configured to selectively switch at least one of the plurality of cells from the non-operational state to an operational state by providing the at least one operating material to the at least one cell.

Abstract: An apparatus for controlling water production in a wellbore comprises a body in the form of a base pipe, the base pipe having an axial flow passage in the form of axial throughbore and a lateral flow passage in the form of radial port. A shroud is disposed around the base pipe and forms a housing of the apparatus. In use, the apparatus forms part of a completion string for location in the wellbore, the apparatus configured to direct production fluid into a production conduit for recovery to surface, perform a quantitative measurement of water content within the production fluid, and vary the fluid flow in the fluid flow path based on the quantitative measurement of water content within the production fluid to maintain water production at or below a predetermined threshold.

Abstract: An applicator system for extrusive dispensing of work material from a flexible pre-charged portion of a cartridge unit is provided. The system comprises a body portion having an actuator and a housing coupled thereto. The housing includes a cartridge bay and an arresting member displaceably coupled thereto. The cartridge bay is configured to receive the cartridge unit and defines at least one containment compartment for receiving the pre-charged cartridge. The arresting member is displaceable between open and closed configurations for releasably retaining the cartridge unit. The actuator, coupled to the housing in communication with the cartridge bay, includes a drive member engaging the pre-charged cartridge within the containment compartment. The body includes a handle and an activation member coupled thereto.

Abstract: A power generator for use in a bore, the power generator comprising at least one drivable member; and at least one generation apparatus; the generation apparatus comprising at least one generator magnet for producing a magnetic field; and at least one electrically conductive member located or locatable within the magnetic field; wherein the drivable member is drivable by fluid flowing in the bore so as to produce relative motion of the at least one magnet and the at least one electrically conductive member in order to induce a current in the at least one electrically conductive member.

Abstract: A turbine has a flow pathway with an inlet in communication with the fluid channel. A rotor is disposed in the flow pathway and is rotatable around a rotation axis under the action of fluid flowing along the flow pathway. The rotation axis of the rotor is oblique to an axis extending along the fluid channel. The outlet of flow pathway may return fluid to the fluid channel. The turbine may also be provided with a flow control arrangement so as to vary the flow of fluid past the rotor and to prevent the rotor from damage. The rotor may be positioned apart from the fluid channel and so as not to obstruct the fluid channel.

Abstract: The invention concerns a method and assay for qualifying equine laminitis disease status in a subject by measuring specific biomarkers, comparing the level of said biomarker to a control level; and correlating the measurement with laminitis disease status, wherein a statistically relevant elevated level of said biomarker is present in said sample relative to said control level. The invention further relates to immuno-based methods and assays for detecting toxins relevant to laminitis and to the use of antibodies for assay and diagnostic purposes.

Abstract: A packaging system includes a loading area configured to receive a product and a pusher assembly including a pusher arm and a support. The pusher assembly is switchable between a bundling orientation and a case packing orientation. In the bundling orientation, the support is disposed at a first end of the pusher arm. In the case packing orientation, the support is disposed at a second end of the pusher aim. The pusher assembly moves the product in a first direction from the loading area, along a bundling path, and to a bundler when in the bundling orientation. Conversely, the pusher assembly moves the product in a second direction from the loading area, along a case packing path, and into a case when in the case packing orientation.

Abstract: There are described downhole devices, methods and other apparatus, which may be used to generate energy, monitor fluids and/or provide control signals or otherwise trigger for actuation. The devices, methods, etc. may provide improved autonomy and/or accuracy, while at the same time minimise any effect on the operation of a well. Such devices and methods may be particularly useful downhole and in remote locations. An example of a device comprises a generating material having a fluid contact surface, that contact surface being configured to be in contact with a fluid downhole. The generating material may be configured to generate an electric charge at the material in response a fluid at the contact surface. In some examples, the device further comprises a signal source configured to provide a signal in response to a generated electric charge at the generating material.

Abstract: The invention concerns the improvement of metabolic and digestive health of humans by providing diagnostic methods for enterometabolic disorders such as IBS and IBD and/or the treatment of IBS and IBD by compositions comprising enzyme rich malt extract (ERME).

Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.